Nature Communications (Jul 2023)

LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis

  • Dan-Pei Li,
  • Li Huang,
  • Ran-Ran Kan,
  • Xiao-Yu Meng,
  • Shu-Yun Wang,
  • Hua-Jie Zou,
  • Ya-Ming Guo,
  • Pei-Qiong Luo,
  • Li-Meng Pan,
  • Yu-Xi Xiang,
  • Bei-Bei Mao,
  • Yu-Yu Xie,
  • Zhi-Han Wang,
  • Min Yang,
  • Rui He,
  • Yan Yang,
  • Zhe-Long Liu,
  • Jun-Hui Xie,
  • De-Lin Ma,
  • Ben-Ping Zhang,
  • Shi-Ying Shao,
  • Xi Chen,
  • Si-Miao Xu,
  • Wen-Tao He,
  • Wen-Jun Li,
  • Yong Chen,
  • Xue-Feng Yu

DOI
https://doi.org/10.1038/s41467-023-40183-3
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Inhibition of immunocyte infiltration and activation has been suggested to effectively ameliorate nonalcoholic steatohepatitis (NASH). Paired immunoglobulin-like receptor B (PirB) and its human ortholog receptor, leukocyte immunoglobulin-like receptor B (LILRB2), are immune-inhibitory receptors. However, their role in NASH pathogenesis is still unclear. Here, we demonstrate that PirB/LILRB2 regulates the migration of macrophages during NASH by binding with its ligand angiopoietin-like protein 8 (ANGPTL8). Hepatocyte-specific ANGPTL8 knockout reduces MDM infiltration and resolves lipid accumulation and fibrosis progression in the livers of NASH mice. In addition, PirB−/− bone marrow (BM) chimeras abrogate ANGPTL8-induced MDM migration to the liver. And yet, PirB ectodomain protein could ameliorate NASH by sequestering ANGPTL8. Furthermore, LILRB2-ANGPTL8 binding-promoted MDM migration and inflammatory activation are also observed in human peripheral blood monocytes. Taken together, our findings reveal the role of PirB/LILRB2 in NASH pathogenesis and identify PirB/LILRB2-ANGPTL8 signaling as a potential target for the management or treatment of NASH.